Multidisciplinary Approach to the Management of Advanced Prostate Cancer

Posted by Daniel P. Petrylak, MD | Jul 2023

Daniel P. Petrylak, MD, presented “Multidisciplinary Approach to the Management of Advanced Prostate Cancer” during the 33rd International Prostate Cancer Update on January 24, 2023, in Vail, Colorado.

How to cite: Petrylak, Daniel P. “Multidisciplinary Approach to the Management of Advanced Prostate Cancer.” January 24, 2023. Accessed May 2024. https://grandroundsinurology.com/multidisciplinary-approach-to-the-management-of-advanced-prostate-cancer/

Multidisciplinary Approach to the Management of Advanced Prostate Cancer – Summary

Daniel P. Petrylak, MD, discusses the benefits of a multidisciplinary approach for prostate cancer survival rates and increased clinical efficiency. He emphasizes the need for a prostate cancer management approach involving urologists, medical oncologists, radiation oncologists, and primary care physicians, with references to nutritionists, mental health professionals, and pain management experts.

Dr. Petrylak highlights existing SEER data results, indicating that men with locally advanced and high-risk prostate cancer experience better outcomes when treated with a multidisciplinary approach. He also reviews the University of Colorado’s data on multidisciplinary teams, noting an increased survival rate at each stage of prostate cancer when compared with regional and state data.

Dr. Petrylak then analyzes the benefits of a multidisciplinary approach for other disease states, including optimized patient outcomes, increased access to specialty therapies, more efficient clinician and patient scheduling, better care coordination, and improved communication. Dr. Petrylak concludes by offering considerations pertaining to healthcare challenges, and advocating for a multidisciplinary approach.

About The 33rd Annual International Prostate Cancer Update:

The International Prostate Cancer Update (IPCU), founded in 1990, is a multi-day CME conference focused on prostate cancer treatment updates with expert, international faculty. It is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer. The 33rd iteration of the meeting occurred January 22-25, 2023 in Vail, Colorado. To view more educational presentations from IPCU 33, visit our collection page.

About The Author

Daniel P. Petrylak, MD

Daniel P. Petrylak, MD, leads the genitourinary cancers medical oncology team at Smilow Cancer Hospital as director of the genitourinary cancer research group, professor, and co-director of the Cancer Signaling Network program. Dr. Petrylak joined Yale from Herbert Irving Cancer Center at Columbia University Medical Center with New York-Presbyterian Hospital, where he served as Professor of Medicine (Medical Oncology) and Urology and began his appointment in September of 2012. Dr. Petrylak is a member of the American Association for Cancer Research (AACR), American Society for Clinical Oncology (ASCO), American College of Physicians (ACP), American Association for the Advancement of Science (AAAS), American Urological Association (AUA), and the Southwest Oncology Group (SWOG). After serving for more than 20 years as the advanced bladder chair for SWOG, Dr. Petrylak is now the Vice Chair of the Genitourinary Committee. He additionally has led multiple national and international studies in prostate and bladder cancer. Dr. Petrylak’s research interests span both prostate and bladder cancer. He led an investigator-initiated trial of docetaxel and estramustine in castration resistant prostate cancer. The results of this study supported a phase 3 trial of this combination in SWOG led by Dr. Petrylak, which in turn, supported the FDA approval of docetaxel for castration resistant prostate cancer. This was one of the first two trials to demonstrate a survival benefit in this state of disease. Dr. Petrylak has also been instrumental in the development of immunotherapy and targeted therapies for refractory bladder cancer. His work with Enfortumab Vedotin has supported the accelerated and full FDA approval of this drug. Dr. Petrylak received his undergraduate degree from Columbia College and his medical degree from Case Western University School of Medicine. He completed his internship and residency at Albert Einstein College of Medicine and his fellowship in medical oncology at Memorial Sloan-Kettering Cancer Center. He has authored more than 200 peer-reviewed articles and book chapters on prostate and bladder cancer research outcomes.

Join the GRU Community

- Why Join? -

Share This

Chat with usLiveChat